JP6987798B2 - 癌の治療に変異体ｉｄｈ１阻害剤として有用なチアゾール誘導体 - Google Patents
癌の治療に変異体ｉｄｈ１阻害剤として有用なチアゾール誘導体 Download PDFInfo
- Publication number
- JP6987798B2 JP6987798B2 JP2018567108A JP2018567108A JP6987798B2 JP 6987798 B2 JP6987798 B2 JP 6987798B2 JP 2018567108 A JP2018567108 A JP 2018567108A JP 2018567108 A JP2018567108 A JP 2018567108A JP 6987798 B2 JP6987798 B2 JP 6987798B2
- Authority
- JP
- Japan
- Prior art keywords
- compound
- atropisomer
- alkyl
- group
- formula
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 0 C*(C)C([C@](C1C)C2C1N*)=C(*)*(**)C2=O Chemical compound C*(C)C([C@](C1C)C2C1N*)=C(*)*(**)C2=O 0.000 description 1
- JTLTXVXSFSNOPN-UHFFFAOYSA-N CCC1C(N(C(C=C(C)C)=C(C=C2c3nc(-c(cc4)ccc4Cl)c[s]3)C(N3CCNCC3)=O)C2=O)=CC(OC)=CC1 Chemical compound CCC1C(N(C(C=C(C)C)=C(C=C2c3nc(-c(cc4)ccc4Cl)c[s]3)C(N3CCNCC3)=O)C2=O)=CC(OC)=CC1 JTLTXVXSFSNOPN-UHFFFAOYSA-N 0.000 description 1
- WOSRIYRLFLMNQC-UHFFFAOYSA-N N#CCc1nc(-c2ccc(C(F)(F)F)nc2)c[s]1 Chemical compound N#CCc1nc(-c2ccc(C(F)(F)F)nc2)c[s]1 WOSRIYRLFLMNQC-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4995—Pyrazines or piperazines forming part of bridged ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/08—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/07—Optical isomers
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662353298P | 2016-06-22 | 2016-06-22 | |
| US62/353,298 | 2016-06-22 | ||
| PCT/US2017/038549 WO2017223202A1 (en) | 2016-06-22 | 2017-06-21 | Thiazole derivatives useful as mutant idh1 inhibitors for treating cancer |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2019518770A JP2019518770A (ja) | 2019-07-04 |
| JP2019518770A5 JP2019518770A5 (OSRAM) | 2020-07-30 |
| JP6987798B2 true JP6987798B2 (ja) | 2022-01-05 |
Family
ID=59276859
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018567108A Active JP6987798B2 (ja) | 2016-06-22 | 2017-06-21 | 癌の治療に変異体ｉｄｈ１阻害剤として有用なチアゾール誘導体 |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US10836759B2 (OSRAM) |
| EP (1) | EP3475276B1 (OSRAM) |
| JP (1) | JP6987798B2 (OSRAM) |
| CN (1) | CN109641887B (OSRAM) |
| AU (1) | AU2017281088B2 (OSRAM) |
| CA (1) | CA3028999A1 (OSRAM) |
| ES (1) | ES2880347T3 (OSRAM) |
| WO (1) | WO2017223202A1 (OSRAM) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2016044782A1 (en) | 2014-09-19 | 2016-03-24 | Forma Therapeutics, Inc. | Phenyl quinolinone derivatives as mutant-isocitrate dehydrogenase inhibitors |
| JP6751081B2 (ja) | 2014-09-19 | 2020-09-02 | フォーマ セラピューティクス，インコーポレイテッド | 変異イソクエン酸デヒドロゲナーゼ阻害剤としてのピリジニルキノリノン誘導体 |
| CA2961793C (en) | 2014-09-19 | 2021-03-16 | Forma Therapeutics, Inc. | Quinolinone pyrimidines compositions as mutant-isocitrate dehydrogenase inhibitors |
| SI3447050T1 (sl) | 2014-09-19 | 2020-08-31 | Forma Therapeutics, Inc. | Derivati piridin-2(1H)-on kinolinona kot inhibitorji mutirane izocitratne dehidrogenaze |
| US9624216B2 (en) | 2015-04-21 | 2017-04-18 | Forma Therapeutics, Inc. | Quinolinone five-membered heterocyclic compounds as mutant-isocitrate dehydrogenase inhibitors |
| US10294206B2 (en) | 2015-04-21 | 2019-05-21 | Forma Tm2, Inc. | Fused-bicyclic aryl quinolinone derivatives as mutant-isocitrate dehydrogenase inhibitors |
| US11013734B2 (en) | 2018-05-16 | 2021-05-25 | Forma Therapeutics, Inc. | Treating patients harboring an isocitrate dehydrogenase-1 (IDH-1) mutation |
| US11576906B2 (en) | 2018-05-16 | 2023-02-14 | Forma Therapeutics, Inc. | Inhibiting mutant IDH-1 |
| US11311527B2 (en) | 2018-05-16 | 2022-04-26 | Forma Therapeutics, Inc. | Inhibiting mutant isocitrate dehydrogenase 1 (mIDH-1) |
| US10532047B2 (en) | 2018-05-16 | 2020-01-14 | Forma Therapeutics, Inc. | Solid forms of ((S)-5-((1-(6-chloro-2-oxo-1,2-dihydroquinolin-3-yl)ethyl)amino)-1-methyl-6-oxo-1,6-dihydropyridine-2-carbonitrile |
| US11013733B2 (en) | 2018-05-16 | 2021-05-25 | Forma Therapeutics, Inc. | Inhibiting mutant isocitrate dehydrogenase 1 (mlDH-1) |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN108524505A (zh) * | 2009-03-13 | 2018-09-14 | 安吉奥斯医药品有限公司 | 用于细胞增殖相关病症的方法和组合物 |
| CA2756347A1 (en) | 2009-03-24 | 2010-09-30 | Gilead Calistoga Llc | Atropisomers of 2-purinyl-3-tolyl-quinazolinone derivatives and methods of use |
| JP2016514124A (ja) * | 2013-03-14 | 2016-05-19 | ノバルティス アーゲー | 変異ｉｄｈの阻害薬としての３−ピリミジン−４−イル−オキサゾリジン−２−オン |
| CN107428690B (zh) * | 2014-12-22 | 2021-04-13 | 美国政府健康及人类服务部 | 可用于治疗癌症的突变idh1抑制剂 |
-
2017
- 2017-06-21 CN CN201780051410.0A patent/CN109641887B/zh active Active
- 2017-06-21 WO PCT/US2017/038549 patent/WO2017223202A1/en not_active Ceased
- 2017-06-21 CA CA3028999A patent/CA3028999A1/en active Pending
- 2017-06-21 EP EP17735296.0A patent/EP3475276B1/en active Active
- 2017-06-21 US US16/312,206 patent/US10836759B2/en active Active
- 2017-06-21 ES ES17735296T patent/ES2880347T3/es active Active
- 2017-06-21 AU AU2017281088A patent/AU2017281088B2/en active Active
- 2017-06-21 JP JP2018567108A patent/JP6987798B2/ja active Active
Also Published As
| Publication number | Publication date |
|---|---|
| JP2019518770A (ja) | 2019-07-04 |
| EP3475276A1 (en) | 2019-05-01 |
| US20190241551A1 (en) | 2019-08-08 |
| CN109641887A (zh) | 2019-04-16 |
| EP3475276B1 (en) | 2021-03-31 |
| ES2880347T3 (es) | 2021-11-24 |
| US10836759B2 (en) | 2020-11-17 |
| CN109641887B (zh) | 2022-09-20 |
| AU2017281088A1 (en) | 2019-01-17 |
| WO2017223202A1 (en) | 2017-12-28 |
| CA3028999A1 (en) | 2017-12-28 |
| AU2017281088B2 (en) | 2021-05-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP6987798B2 (ja) | 癌の治療に変異体ｉｄｈ１阻害剤として有用なチアゾール誘導体 | |
| JP6901394B2 (ja) | 癌の処置に有用な変異型ｉｄｈ１阻害剤 | |
| US9187474B2 (en) | Raf inhibitor compounds | |
| US20170056382A1 (en) | Compounds and methods for kinase modulation, and indications therefor | |
| JP2008545652A (ja) | ｃ−ｋｉｔおよびｃ−ｆｍｓ活性を調節する化合物およびその用途 | |
| US8580815B2 (en) | Derivatives of azaindoles as inhibitors of protein kinases ABL and SRC | |
| KR20220066074A (ko) | A2a / a2b 억제제로서의 트리아졸로피리미딘 | |
| JP2021519828A (ja) | ジアリール大員環化合物、医薬組成物及びその用途 | |
| TW201731841A (zh) | 6‐芳基或6‐異芳基‐4‐嗎啉‐4‐芳基‐吡啶‐2‐酮化合物 | |
| CN110357905A (zh) | 作为蛋白激酶抑制剂的大环类衍生物及其制备方法和用途 | |
| JP2007500130A (ja) | ベンゾジアゼピン受容体リガンドである、イミダゾ−ピリミジン及びトリアゾロ−ピリミジン | |
| WO2013081094A1 (ja) | イミダゾ［１，２－ａ］ピリジン誘導体及びその医薬用途 | |
| US20240002365A1 (en) | Pyridazine and 1,2,4-triazine derivatives as fgfr kinase inhibitors | |
| US20240190864A1 (en) | Bruton's Tyrosine Kinase (BTK) INHIBITOR AND APPLICATION THEREOF |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20190716 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20190802 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20200619 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20200619 |
|
| A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20210520 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A132 Effective date: 20210525 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20210824 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20211102 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20211201 |
|
| R150 | Certificate of patent or registration of utility model |
Ref document number: 6987798 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |